WHO | Definitions
dose related to the pharmacological properties. 8 Signal • Possible causal relationship adverse event and drug • Previously unknown or incompletely documented • More than one report is needed. Depending on: – Quality of the information – Seriousness of the event. 9
Download WHO | Definitions
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
Site Master File final EU
ec.europa.eu- Toxic or hazardous substances handled (e.g. with high pharmacological activity and/or with sensitising properties); - Product types manufactured in a dedicated facility or on a campaign basis, if applicable; - Process Analytical Technology (PAT) applications, if applicable: general
Xylazine - United States Department of Justice
www.deadiversion.usdoj.govproperties. concentration ranges from . Chemistry The chemical structure of xylazine is shown below. Xylazine is structurally similar to the class of compounds known as phenothiazines. The molecular formula is C. 12H16N2S with a molecular weight of 220.34 g/mol. The Chemical Abstract Service (CAS) number is 7361- 61-7. The
Guideline on the chemistry of active substances
www.ema.europa.eurelevant properties of the active substance should be provided, in particular physico -chemical properties that affect pharmacological efficacy and toxicological safety such as solubilities, acid dissociation constant ( pKa), polymorphism, isomerism, partition coefficient ( logP), permeability, hygroscopicity and any other relevant properties .
S6(R1) Step 5 Preclinical safety evaluation of ...
www.ema.europa.eustudies to assess pharmacological activity, including defining mechanism(s) of action, are often used to support the rationale of the proposed use of the product in clinical studies. For monoclonal antibodies, the immunological properties of the antibody should be described in
7. INVESTIGATOR’S BROCHURE
www.med.upenn.edu7.3.4 Physical, Chemical, and Pharmaceutical Properties and Formulation A description should be provided of the investigational product substance(s) (including the chemical and/or structural formula(e)), and a brief summary should be given of the relevant physical, chemical, and pharmaceutical properties.